Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-27T05:47:47.859Z Has data issue: false hasContentIssue false

Assessment of a new self-rating scale for post-traumatic stress disorder

Published online by Cambridge University Press:  01 January 1997

J. R. T. DAVIDSON
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
S. W. BOOK
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
J. T. COLKET
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
L. A. TUPLER
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
S. ROTH
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
D. DAVID
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
M. HERTZBERG
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
T. MELLMAN
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
J. C. BECKHAM
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
R. D. SMITH
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
R. M. DAVISON
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
R. KATZ
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA
M. E. FELDMAN
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, Department of Psychology, Duke University and Veterans Administration Medical Center, Durham, NC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC; Department of Psychiatry, University of Miami, FL; and Ciba-Geigy Pharmaceuticals, Summit, NJ, USA

Abstract

Background. In post-traumatic stress disorder (PTSD) there is a need for self-rating scales that are sensitive to treatment effects and have been tested in a broad range of trauma survivors. Separate measures of frequency and severity may also provide an advantage.

Methods. Three hundred and fifty-three men and women completed the Davidson Trauma Scale (DTS), a 17-item scale measuring each DSM-IV symptom of PTSD on 5-point frequency and severity scales. These subjects comprised war veterans, survivors of rape or hurricane and a mixed trauma group participating in a clinical trial. Other scales were included as validity checks as follows: Global ratings, SCL-90-R, Eysenck Scale, Impact of Event Scale and Structured Clinical Interview for DSM-III-R.

Results. The scale demonstrated good test–retest reliability (r = 0·86), internal consistency (r = 0·99). One main factor emerged for severity and a smaller one for intrusion. In PTSD diagnosed subjects, and the factor structure more closely resembled the traditional grouping of symptoms. Concurrent validity was obtained against the SCID, with a diagnostic accuracy of 83% at a DTS score of 40. Good convergent and divergent validity was obtained. The DTS showed predictive validity against response to treatment, as well as being sensitive to treatment effects.

Conclusions. The DTS showed good reliability and validity, and offers promised as a scale which is particularly suited to assessing symptom severity, treatment outcome and in screening for the likely diagnosis of PTSD.

Type
Research Article
Copyright
© 1997 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)